A Phase 2 Study of INotuzumab Ozogamicin (NSC# 772518, IND #133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Cancer Research -
Location
-
Principal Investigator
-
Sponsor
Children's Oncology Group
The overall goal of this study is to find out what effect, good and/or bad, the drug inotuzumab ozogamicin has on children and young adults with relapsed or refractory B-ALL.
Enrollment Form
This study is currently enrolling.